Octreotide Pamoate
Carcinoid
RayzeBio, Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Carcinoid cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide RayzeBio, Inc. | Phase 3 | BB |
Paltusotine Crinetics Pharmaceuticals Inc. | Phase 3 | BB |
Everolimus RayzeBio, Inc. | Phase 3 | B |
Lanreotide RayzeBio, Inc. | Phase 3 | B |
DOTATOC British Columbia Cancer Agency | Phase 2 | B |
View all 30 →
Same molecule, other indications
Octreotide Pamoate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →